A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Ardelyx

    • Most Recent Events

    • 28 Feb 2017 Results assessing safety and efficacy of tenapanor, published in the American Journal of Gastroenterology
    • 19 Oct 2016 Results published in the Ardelyx Media Release.
    • 19 Oct 2016 According to Ardelyx media release, company will present secondary endpoint findings in an oral session today during the American College of Gastroenterology (ACG) Annual Scientific Meeting and Post Graduate Course 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top